| ID | Type | Location (GRCh37) | Location (GRCh38) | Length | GC content |
|---|---|---|---|---|---|
| hsa_ITCH_0017500 | Exon-Exon | chr20:33027960-33030108 | chr20:34440155-34442303 | 286 nt | 0.4685 |
| hsa_ITCH_0017600 | Exon-Exon | chr20:33027960-33037285 | chr20:34440155-34449480 | 531 nt | 0.4595 |
| hsa_ITCH_0017700 | Exon-Exon | chr20:33027960-33045279 | chr20:34440155-34457474 | 616 nt | 0.4578 |
| hsa_ITCH_0017800 | Exon-Exon | chr20:33027960-33050026 | chr20:34440155-34462221 | 745 nt | 0.4497 |
| hsa_ITCH_0017900 | Exon-Exon | chr20:33027960-33059320 | chr20:34440155-34471515 | 890 nt | 0.4472 |
| hsa_ITCH_0018000 | Exon-Exon | chr20:33027960-33067594 | chr20:34440155-34479789 | 1139 nt | 0.4372 |
| hsa_ITCH_0018100 | Exon-Exon | chr20:33027960-33069011 | chr20:34440155-34481206 | 1414 nt | 0.4201 |
| hsa_ITCH_0018800 | Exon-Exon | chr20:33030013-33033266 | chr20:34442208-34445461 | 271 nt | 0.4797 |
| hsa_ITCH_0018900 | Exon-Exon | chr20:33030013-33037285 | chr20:34442208-34449480 | 341 nt | 0.4604 |
| hsa_ITCH_0019000 | Exon-Exon | chr20:33030013-33050026 | chr20:34442208-34462221 | 555 nt | 0.4468 |
A review consolidating research in humans and model organisms indicates that the circITCH functions as a tumor suppressor in glioma by sponging miR-214 to allow expression of ubiquitin-protein ligase E3, thereby suppressing proliferation and preventing apoptosis, while also targeting the Wnt/β-catenin pathway [Mehta et al. DOI:10.1016/j.pneurobio.2020.101746]. In oesophageal squamous cell carcinoma, the circITCH is downregulated and increases ITCH expression to inhibit the Wnt/β-catenin pathway [Lee et al. DOI:10.1016/j.biopha.2018.12.052]. circITCH hsa_circ_0001141 (circITCH) was found to be lower in the hearts of cancer patients suffering from doxorubicin-induced cardiomyopathy compared to those with dilated cardiomyopathy, hypertrophic cardiomyopathy, and healthy donors, and its expression ameliorates doxorubicin-induced cardiomyocyte injury [Tian et al. DOI:10.3390/molecules26041155].